Het primaire doel is om de werkzaamheid te onderzoeken van filgotinib versus placebo voor de behandeling van signalen en symptomen van niet-infectieuze intermediaire uveitis, posterieure uveitis en pan-uveitis na 24 weken.
Merus B.V. in Utrecht, a leader in developing best-in-class bispecific antibody therapeutics to treat cancer patients, announced the initiation of a phase I/II clinical study of MCLA-128 for the treatment of solid tumors. MCLA-128 is an ADCC-enhanced, full-length IgG bispecific antibody that simultaneously targets the growth factor receptors HER2 and HER3. “Tumors with intrinsic or acquired resistance to… Read More »